Stock screenerAll disclosures →
EDGAR →
NERV
Conviction 47HealthcareScan · Fri, Jun 26, 2026NERV$4.38+6.57%
ResistanceSupportVol 14Vol MA14 219.85K
Mar 27Apr 15May 4May 20Jun 9Jun 26
Price4.38
Change+6.57%
Gap+4.74%
Rel volume6.81×
Avg volume185.74K
Avg $ vol832.86K
SMA 204.57
SMA 505.39
SMA 2004.72
Price vs 50-18.66%
Price vs 200-7.28%
MA stackmixed
50/200 cross—
Supertrenddown · 5.39
RSI (14)42
MACD hist0.02
MACD crossbull · 4d
Stoch %K / %D32 / 22
ADX (14)24
+DI / −DI11 / 21
RSI divergenceBullish
MACD divergenceBullish
ATR %+9.17%
ADR %8.35%
52w high8.07
52w low1.63
From 52w high-45.72%
Above 52w low+168.71%
New 52w highNo
SqueezeOn · 5d
Bollinger width20.22%
%B0.30
Donchian pos30.16%
Donchian high5.26
Donchian low4.00
AVWAP (52w high)7.85
vs AVWAP high-44.17%
AVWAP (52w low)7.47
vs AVWAP low-41.37%
OBV trendFlat
Chaikin MF (20)0.02
Today vs 20d6.81×
Avg vol (14d)219.85K
Avg vol (20d)185.74K
Avg $ vol (20d)832.86K
Market cap—
RS 3m (vs SPY)-44.42%
RS 6m (vs SPY)-3.96%
RS line new highNo
Trend template4/8
Technical rank35.5
1 week-2.01%
1 month-16.73%
3 months-28.66%
6 months+7.88%
1 year+140.66%
YTD+11.73%
P/E-0.65
P/B-0.75
P/S—
P/FCF-14.16
EPS-34.67
Div yield—
ROE115.51%
ROA-312.06%
Debt/Eq-0.04
Current17.65
EV/EBITDA-11.15
Gross margin—
Net margin—
Rev growth—
EPS growth—
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value168.21M
Revenue0
Net income-125.4M
Gross profit—
Free cash flow-13.53M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out46.59M
Employees7
ListedTue, Jul 1, 2014
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeC
Conviction47 / 100
Pattern quality—
Tech rank35.5 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance5.40
Support4.18
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in NERV
No recent disclosed trades by Congress in NERV. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in NERV · 8 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Laghrissi-Thode Fouzia Director · Stock Option (right to buy) · 2026-06-03 | Grant | 50K | $0 | 2026-06-03 | 2026-06-05 |
VAN HEEK G JAN Director · Stock Option (right to buy) · 2026-06-03 | Grant | 50K | $0 | 2026-06-03 | 2026-06-05 |
HASLER HANS PETER Director · Stock Option (right to buy) · 2026-06-03 | Grant | 50K | $0 | 2026-06-03 | 2026-06-05 |
Kupfer David Director · Stock Option (right to buy) · 2026-06-03 | Grant | 50K | $0 | 2026-06-03 | 2026-06-05 |
Luthringer Remy CEO · Employee Stock Option (right to buy) · 2026-06-03 | Grant | 1.69M | $0 | 2026-06-03 | 2026-06-05 |
Kaul Inderjit Director · Stock Option (right to buy) · 2026-06-03 | Grant | 50K | $0 | 2026-06-03 | 2026-06-05 |
Ahlholm Frederick W SVP, CFO and Secretary · Employee Stock Option (right to buy) · 2026-06-03 | Grant | 680K | $0 | 2026-06-03 | 2026-06-05 |
O'Connor James Joseph Chief Business Officer and GC · Employee Stock Option (right to buy) · 2026-04-21 | Grant | 350.8K | $0 | 2026-04-21 | 2026-04-22 |
SEC filings
EDGAR filings in NERV · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.